Guardant Health, Inc. Overview
Pro stress-test →Guardant Health is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research.
Strategic Profile
Pro stress-test →In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. The company is positioned at the intersection of precision oncology and diagnostic innovation, with recent strategic partnerships like the multi-year collaboration with Merck announced in January 2026. Clinical validation, regulatory wins, and operational efficiencies are improving reimbursement prospects and accelerating the company's path to profitability.
Competitive Landscape
Pro stress-test →Exact Sciences is one of Guardant Health's main competitors. The company operates in the precision oncology and liquid biopsy space alongside players like Natera and Illumina. Illumina and Guardant Health settled their dispute in 2023, signed a long-term supply agreement, and agreed to share specimen samples for cancer research.
Industry Context
Guardant Health, Inc. operates in Precision Oncology & Liquid Biopsy Diagnostics.
Key facts
Founded: 2012 · Headquarters: Palo Alto, US · Employees: ~1,400 · Revenue: $903M · Market cap: $13.6B